Jefferies analyst Chris Howerton downgraded UroGen Pharma to Hold from Buy with a price target of $10, down from $35, citing commercial underperformance as well as sector sentiment and capital risk.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on URGN:
